QPS Announces New Laboratory Services for Clinical Trials and Cell Therapy Development
QPS, a leading global contract research organization (CRO), is pleased to announce new laboratory services capabilities. The central laboratory, leukopak cell therapy facility, and enhanced PBMC capabilities will complement existing bioanalysis, translational medicine and peripheral blood mononuclear cell (PMBC) laboratories and extend the current QPS full-service global CRO offerings.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626261072/en/
QPS Missouri, a division of QPS Holdings, LLC, a global Contract Research Organization. QPS Missouri conducts Phase I-IV clinical trials and houses central lab, safety lab, PBMC and cell production services in Springfield, Missouri. (Photo: Business Wire)
QPS now offers clinical trial sample analysis services and leukopak cell therapy products from its newly expanded clinical trials unit conveniently located in Springfield, Missouri. In addition, QPS has also expanded PBMC service offerings from its Miami, Florida location into its Springfield, Missouri laboratories. The new facilities are housed with an existing clinical (safety) laboratory, a modern self-contained pharmacy, and dedicated space to build and ship clinical trial kits.
The modern central laboratory for sample analysis complements the existing on-site safety laboratory, equipped with the most up-to-date technologies for chemistry, urinalysis, serology, coagulation, and hematology testing. These capabilities, designed to monitor subject safety during ongoing clinical trials, will remain as core services for QPS in-house clinical trials.
The new leukopak products collection and processing facility is designed to meet the exponential growing demand for blood products to support cell therapy research and QPS is ideally placed to provide this service. QPS Missouri has a database of over 35,000 potential study participants, who can be contacted as potential blood donors for leukopak products.
“There is significant unmet demand in this rapidly growing area of cell therapy products, which represents a tremendous opportunity for QPS. Over 3,000 cell and gene therapy programs are currently in progress representing a 20% increase over the past five years. These programs require leukopak products to move forward, and as a result this market is forecasted to grow by a CAGR of more than 8% over the next six years,” said Benjamin Chien, Chairman, President and CEO of QPS.
The enhanced PBMC services include a new PBMC processing lab at the Springfield location, complementing the existing lab at QPS Miami in Miami, Florida. This new lab will support a current unmet need for PBMC processing in the midwestern USA. PBMC sample analysis is a time-consuming process, typically required in vaccine trials, and it is best done in a lab adjacent to the clinical trial unit. QPS is uniquely positioned to offer this service.
“These new facilities, services and products extend our full service CRO capabilities, putting QPS in a position to offer clients comprehensive clinical research services in one location. The central lab, PBMC lab, and the leukopack facility complement and enhance our current 240 bed clinical trials unit, safety laboratory, modern self-contained pharmacy, and clinical trial kit production facility,” said Brendon Bourg, Vice President, Early Phase Clinical and Head of Administration at QPS Missouri.
ABOUT QPS HOLDINGS, LLC
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626261072/en/
Contacts
Gabrielle Pastore
1-302-635-4290
Gabrielle.Pastore@qps.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HyperLight Launches 110GHz Intensity Modulator with Record low Vπ, Leveraging Its TFLN Chiplet ™ Platform25.3.2025 17:00:00 CET | Press Release
HyperLight, creator of the TFLN Chiplet™ platform, today announced the launch of its groundbreaking 110 GHz Low Vπ Intensity Modulator, featuring industry-standard optical fiber and microwave connectors. This industry-first device significantly advances electro-optic modulation capabilities for critical applications, including 400 Gbps-per-lane testing, 100 GHz+ photodiode calibration, high-frequency radio-over-fiber systems, and various other cutting-edge technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325461709/en/ HyperLight's New 110 GHz Low Vπ Intensity Modulator with Record Low 1.4V Half-Wave Voltage Leveraging HyperLight's proprietary TFLN Chiplet™ platform, this revolutionary modulator achieves an unprecedented half-wave voltage (Vπ) of just 1.4 V with bandwidth performance exceeding 110 GHz—setting a new benchmark in high-bandwidth modulation. Combining ultra-low Vπ with minimal insertion loss and ex
Neural Potential: Mouser Series Explores Brain Computer Interfaces at the Intersection of Technology and the Mind25.3.2025 16:18:00 CET | Press Release
Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, today announced the release of the latest installment of the Empowering Innovation Together(EIT) technology series, which examines the rapidly evolving field of brain-computer interfaces (BCIs). This series takes a deep dive into the engineering challenges and opportunities in the development of mind-controlled systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325376038/en/ BCIs create direct communication between the brain and external devices, enabling applications like motor function restoration for individuals with paralysis, speech enhancement for those with communication impairments, and even cognitive augmentation. These systems rely on electrode-based neural signal acquisition and advanced signal processing algorithms to translate brain activity into actionable commands. In th
New Milestone as Sweden Enshrines Policy That Can Turn World Smoke-Free25.3.2025 15:57:00 CET | Press Release
Sweden has enshrined tobacco harm reduction in public health policy after becoming the first nation to prove it’s the most effective path to a smoke-free future. Thanks to Sweden’s stance on safer nicotine alternatives, just 4.5% of Swedish-born adults now smoke - below the 5% smoke-free threshold. This success has led Parliament to formally adopt harm reduction, reinforcing Sweden’s role as a global leader in public health innovation. Dr. Delon Human, leader of Smoke Free Sweden, says: “Swedes have participated in a long-running harm reduction experiment, providing undeniable proof that replacing smoking with smokeless nicotine dramatically reduces smoking-related disease, disability and premature deaths - a net gain for public health, while reducing expenditure. “With harm reduction now policy in Sweden, every public health decision will reflect this approach. Other countries should adopt Sweden’s model without further delay.” Rather than reducing tobacco use, Sweden now prioritises
Neos Kicks Off Global Indie Game Publishing Business25.3.2025 15:00:00 CET | Press Release
Neos has launched "IndieTech Games," a label dedicated to publishing high-quality indie games worldwide, including in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320035646/en/ IndieTechGames Neos entered the game development and publishing business for Nintendo Switch in 2019, starting with the release of "Shin chan: Me and the Professor on Summer Vacation - The Endless Seven-Day Journey" in Japan in 2021. The title later expanded to Asia, Europe, and North America in the following year, and eventually to the rest of the world, achieving cumulative shipments of over 500,000 units. The latest title, "Shin chan: Shiro and the Coal Town," has also been released globally and has been well received, following the success of its predecessor with cumulative shipments exceeding 300,000 units. Through the sales and marketing of our in-house developed titles, we have had more opportunities to engage with games from around
Fluidstack to Deploy Energy Efficient Exascale GPU Clusters in Europe in Collaboration With Borealis Data Center, Dell Technologies and NVIDIA25.3.2025 14:00:00 CET | Press Release
Fluidstack, the AI Cloud Platform, today announced it is deploying and managing Exascale clusters across Iceland and Europe in collaboration with Borealis Data Center, Dell Technologies and NVIDIA. The clusters will allow Fluidstack to further deliver a wider array of service options and meet the strong demand for its service offerings from customers around the world. “Our mission has always been to support the most exceptional AI labs, researchers and enterprises on the planet,” said Cesar Maklary, co-founder and president of Fluidstack. “In collaboration with Borealis, Dell and NVIDIA, we can rapidly deploy high-density GPU supercomputers for both European and global customers, all while using 100% renewable energy.” Sustainable Growth with Borealis Borealis Data Center, a leader in green data center infrastructure, will provide Fluidstack with facilities powered by 100% renewable energy. Located in Iceland and operating across the Nordics, Borealis’ facilities benefit from a cold cl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom